ANTISENSE THERAPY AND ITS UNIQUE APPLICATION TO TREAT GENETIC DISORDERS-A REVIEW"

International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 4, page no.194-200, April-2019, Available :http://www.jetir.org/papers/JETIR1904F35.pdf

Authors: Ganesh S. Waghule.
 
Abstract:
A genetic disorder is a genetic problem caused by one or more abnormalities formed in the genome. Most genetic disorders are quite rare and affect one person in every several thousands or millions. Genetic disorders may be hereditary, meaning that they are passed down from the parents' genes. In other genetic disorders, defects may be caused by new mutations or changes to the DNA. The principle behind the technology is that an antisense nucleic acid sequence base pairs with its complementary sense RNA strand and prevents it from being translated into a protein or the inhibition of RNA processing yields the therapeutic result.The Oligonucleotide are used to block coded massage carried by mRNA this known as antisense therapy the primary sequence of mRNA called oligonucleotide contains nucleic acid bases complimentry to mRNA molecule. An oligonucleotide has a complimentry base sequence called antisense oligonucleotide, when mixed with mRNA antisense oligonucleotide Recognize mRNA and forms duplex and act as barrier to translation process and block protein synthesis. Antisense drugs have the potential therapeutic efficacy in the treatment of various diseases than the conventional drug. The rapid development of antisense technology offers almost unlimited scope for the development of new and highly specific therapeutics. Antisense therapeutics therefore is well positioned to play a significant role in the progression of antisense technology for drug development in human diseases. 
 
Key Words:
Antisense therapy, genetic disorder, oligonucleotide, protein, Nucleic acid. 
 

 
 
 
Publication Details:
 
Published Paper ID: JETIR1904F35
 
Published In: Volume 6 | Issue 4 | Year April-2019
 
Page No: 194-200